Skip to content
MARKETS / NASDAQ / ARGX
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Argenx SE ARGX

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$4.2B
▲ 89.9% YoY
$1.3B
▲ 55.1% YoY
$679.0M
In brief

What this company does

argenx SE has established its own sales force in the U.S., Japan, Europe and Canada to commercialize VYVGART for the treatment of gMG and CIDP. It utilizes third-party contract manufacturers that operate in accordance with the FDA's current good manufacturing practices for the manufacture of drug substances and drug products. As of December 31, 2025, it had 1,863 full-time employees, including fully staffed commercial teams in the U.S., Europe, Japan and Canada. VYVGART is approved in more than 30 countries, across three indications and three presentation forms. Its Immunology Innovation Program has over 25 active programs. argenx SE was incorporated under the laws of the Netherlands on April 25, 2008, as a private company with limited liability. On April 26, 2017, it converted to a Dutch European public company with limited liability (Societas Europaea).

Written from the business description in ARGENX SE's annual report to the U.S. Securities and Exchange Commission, filed 19 March 2026. Every sentence was checked against that document before publication.

Growth
USD 4.2B
Revenue, FY2025 · full 11-year series below
Revenue $B Net income $B
FY2025 · Revenue 4.2 · Net income 1.3
2.00B4.00B-0.25B-0.50B201520172019202120232025
Compound annual growth
+118.0%
+151.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +151.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
31 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 25.4% · Net 31.1%
-500%-1000%201520172019202120232025
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 679.0
250.0M500.0M-400.0M-800.0M201520172019202120232025

Total assetsUSD 8.7B
CashUSD 3.5B
Current ratio5.23×

Not available: we don't have the total debt figure for this period.

The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015
Revenue $B4.22.21.20.40.50.00.1····
Operating income $B1.1−0.0−0.4−0.7−0.3−0.5−0.2····
EBITDA $B···········
Income tax $B−0.0−0.7−0.0−0.00.00.00.0····
Net income $B1.30.8−0.3−0.7−0.4−0.6−0.2····
Free cash flow $B0.7−0.1−0.4−0.9−0.6−0.40.1−0.1−0.00.0−0.0
EPS, diluted $19.5712.78−5.16−13.05−7.99−13.40−4.69····
Dividend / sh $···········
Payout %···········
ROE %···········
Shares out B0.060.060.060.060.050.050.040.040.030.020.02

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 5 failures in 40 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 51 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente5 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code P7
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image